EGFR and non-small cell lung carcinoma: For patients with EGFR mutations, molecularly targeted drugs such as tyrosine kinase inhibitors (TKIs) have become a new treatment strategy following surgery and radiotherapy, particularly for patients with advanced NSCLC [12, 13].